Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M

Published byLynette Barker Modified over 5 years ago

Similar presentations

Presentation on theme: "Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M"— Presentation transcript:

1 Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer 
Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M. Correa, PhD, Jennifer M. Bell, BSN, Boris Sepesi, MD, David C. Rice, MD, Ara A. Vaporciyan, MD, Garrett L. Walsh, MD, Reza J. Mehran, MD, Stephen G. Swisher, MD, Bryan F. Meyers, MD  The Annals of Thoracic Surgery  Volume 101, Issue 1, Pages (January 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Pathologic complete response (pCR) in men and women. There was a trend toward more frequent pCR among female patients. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Patients with pathologic complete response (pCR) achieved significantly longer 5-year survival than did those without pCR (85% versus 41%). Median survival among those without pCR was 30.2 months. Median survival among the entire group was 68.4 months, and median survival among those with pCR was not reached. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M"

Similar presentations

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,
Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival  Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival  Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases
Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G
Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery 

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery 

Similar presentations

Ads by Google